The archive · Developer & Business Tools · Product decision · 2014–2026
SciSpace BioMed Agent: research copilot bets domain agents beat ChatGPT
SciSpace's BioMed Agent wires 150+ biomedical tools into one AI prompt; launched Dec 8 2025, ranked #3 on Product Hunt with 410 votes.
SciSpace (formerly Typeset)
What the business is
SciSpace is an AI research platform (formerly Typeset) that hosts 200M+ papers for search, reading, writing and formatting; BioMed Agent is a specialized add-on that runs biomedical workflows — variant interpretation, omics analysis, cloning/CRISPR design, drug discovery — from a single prompt.
Starting capital：Pre-Series A of $850K in Sept 2017 from Haresh Chawla, who had already invested personally since 2015 (Inc42).
How it started
Typeset was ideated in late 2014 and launched publicly in mid-2017 by Saikiran Chandha and Shanu Kumar in Bengaluru, targeting the fragmented academic-writing workflow: four or five separate tools and about 20 steps to submit a paper. It raised $850K in pre-Series A funding in September 2017 from Haresh Chawla, and within three months of launch reported more than 11,000 researchers across 103 countries using the platform, including users at CERN, NASA, ETH Zurich, Stanford and MIT.
What happened
The company rebranded to SciSpace and grew into an AI research platform with a 200M+ paper corpus, 100,000+ journal templates and, per partner materials, over 1 million researchers in 100+ countries. In August 2025 it launched the general-purpose SciSpace Agent; the team then concluded that biomedical work needed deeper specialization — paywalled literature, disconnected omics and clinical datasets, and discipline-specific tools. On December 8 2025 it launched BioMed Agent, an AI co-scientist that chains 150+ biomedical software/tools and curated databases through one prompt, handling variant interpretation, single-cell and multi-omics analysis, CRISPR/cloning design and experimental workflows. It finished #3 on Product Hunt's daily leaderboard with 410 votes, and the founder posted on IndieHackers the same day asking the community whether an integrated AI co-scientist solved a real pain point.
How it ended up
Still live and expanding as of 2026-09-02: BioMed Agent launched on schedule, ranked #3 on Product Hunt's daily board, and remains an add-on inside SciSpace's platform; no company-level end state such as shutdown, exit or dedicated funding round had been announced.
Background
SciSpace BioMed Agent is an AI co-scientist for biomedical research, launched December 8 2025 by SciSpace, the platform formerly known as Typeset. Its pitch is that biomedical researchers still juggle ten or more disconnected tools for one analysis — literature search in one place, pathway tools elsewhere, variant interpretation on another site — so it chains more than 150 biomedical software tools and curated databases behind a single prompt.
SciSpace began in 2014-17 as Typeset, a Bengaluru writing and auto-formatting platform for academic papers, backed by an $850K pre-Series A in 2017. It grew into a research platform hosting 200M+ papers, then added AI: the general SciSpace Agent in August 2025, followed two months later by the biomedical specialist. The BioMed Agent automates variant interpretation, single-cell and multi-omics analysis, cloning and CRISPR design, and experimental workflows, and can generate publication-ready biomedical illustrations.
The launch ranked #3 on Product Hunt's daily board on December 8 2025 with 410 upvotes, and founder Saikiran Chandha asked the IndieHackers community the same day whether an integrated AI co-scientist solved a real pain point. The design bet was explicit: unlike ChatGPT-style general tools, the agent grounds every step in curated biomedical databases and domain-specific pipelines to avoid hallucinated references and workflows that 'sound right but don't hold up scientifically.'
What has to be true
- Fragmentation is the product pain: one analysis spans many tools and tabs, and BioMed Agent collapses that chain into a single prompt.
- Grounding over general chat: curated databases and domain tools are meant to eliminate hallucinated references, which is existential in clinical and drug-discovery settings.
- A corpus moat: 200M+ hosted papers and an existing researcher user base gave SciSpace distribution and data a new entrant would lack.
- Vertical-first sequencing: it proved the general Agent first (Aug 2025), then specialized into biomedicine where risk — and willingness to pay — are highest.
What can be applied
A general assistant wins breadth; a domain agent wins trust. SciSpace grounded BioMed Agent in curated databases because in biomedicine a hallucinated citation is a liability, not a bug.
Aftermath
As of 2026-09-02 BioMed Agent is live as an add-on within SciSpace's research platform; the company continues operating its broader suite (paper discovery, Copilot reading assistance, writing and formatting tools) with claimed scale of 200M+ hosted papers and 1M+ researchers from 100+ countries per its Turnitin partner page. SciSpace's own launch materials describe BioMed Agent as coexisting with the general Agent rather than replacing it. Adoption, revenue and pricing specifics for the BioMed Agent itself had not been disclosed as of the as-of date, and no shutdown or exit had been announced.
Sources
- Would biomedical research be easier if all your tools worked from a single prompt?
- producthunt-daily-2025-12-09 (SciSpace BioMed Agent #3, 410 votes)
- With Its Userbase In 103 Countries Already, Consumer SaaS Startup Typset Gains $850K Funding
- SciSpace partner page (200M+ papers, 1M+ researchers)
spotted an error? The archive wants to know.
Your turn
You just read one. Describe what you are building, and see who is betting on the same thing.
Free account · 3 free questions · no card